BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 2539685)

  • 1. Pharmacokinetics of oral fluconazole in autologous bone marrow transplantation recipients given TBI and high-dose melphalan.
    Milliken S; Powles R; Jones A; Helenglass G
    Transplant Proc; 1989 Feb; 21(1 Pt 3):3067. PubMed ID: 2539685
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of Ewing's sarcoma with high-dose melphalan and autologous bone marrow transplantation.
    Cornbleet MA; Corringham RE; Prentice HG; Boesen EM; McElwain TJ
    Cancer Treat Rep; 1981; 65(3-4):241-4. PubMed ID: 7016319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma pharmacokinetics of high-dose oral melphalan in patients treated with trialkylator chemotherapy and autologous bone marrow reinfusion.
    Choi KE; Ratain MJ; Williams SF; Golick JA; Beschorner JC; Fullem LJ; Bitran JD
    Cancer Res; 1989 Mar; 49(5):1318-21. PubMed ID: 2645050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study.
    Lazarus HM; Blumer JL; Yanovich S; Schlamm H; Romero A
    J Clin Pharmacol; 2002 Apr; 42(4):395-402. PubMed ID: 11936564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized trial of fluconazole versus low-dose amphotericin B in prophylaxis against fungal infections in patients undergoing hematopoietic stem cell transplantation.
    Koh LP; Kurup A; Goh YT; Fook-Chong SM; Tan PH
    Am J Hematol; 2002 Dec; 71(4):260-7. PubMed ID: 12447954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antifungal prophylaxis with low-dose fluconazole during bone marrow transplantation. The Bone Marrow Transplantation Team.
    Alangaden G; Chandrasekar PH; Bailey E; Khaliq Y
    Bone Marrow Transplant; 1994 Dec; 14(6):919-24. PubMed ID: 7711669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Melphalan-total body irradiation and autologous bone marrow transplantation for adult acute leukemia beyond first remission.
    Mehta J; Powles R; Singhal S; Horton C; Tait D; Treleaven J
    Bone Marrow Transplant; 1996 Jul; 18(1):119-23. PubMed ID: 8832004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic interaction between voriconazole and ciclosporin A following allogeneic bone marrow transplantation.
    Groll AH; Kolve H; Ehlert K; Paulussen M; Vormoor J
    J Antimicrob Chemother; 2004 Jan; 53(1):113-4. PubMed ID: 14657088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Posaconazole serum level on day 2 predicts steady state posaconazole serum level.
    Green MR; Woolery JE
    Ther Drug Monit; 2012 Feb; 34(1):118-9. PubMed ID: 22249348
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacokinetics of itraconazole oral solution in allogeneic bone marrow transplant patients receiving total body irradiation.
    Michallet M; Persat F; Kranzhöfer N; Levron JC; Prat C; Belhabri A; Chwetzoff E; Le Moing JP; Fiere D; Piens MA
    Bone Marrow Transplant; 1998 Jun; 21(12):1239-43. PubMed ID: 9674858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of advanced Hodgkin's disease with high dose melphalan and autologous bone marrow transplantation.
    Russell JA; Selby PJ; Ruether BA; Mbidde EK; Ashley S; Zulian G; Berry J; Houwen B; Jones AR; Poon MC
    Bone Marrow Transplant; 1989 Jul; 4(4):425-9. PubMed ID: 2673463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infection prevention in autologous bone marrow transplantation and the role of protective isolation.
    Dekker AW; Verdonck LF; Rozenberg-Arska M
    Bone Marrow Transplant; 1994 Jul; 14(1):89-93. PubMed ID: 7951125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hematopoietic recovery following autologous bone marrow transplantation in a nonhuman primate: effect of variation in treatment schedule with PEG-rHuMGDF.
    Farese AM; MacVittie TJ; Roskos L; Stead RB
    Stem Cells; 2003; 21(1):79-89. PubMed ID: 12529554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Melphalan and total body irradiation (TBI) versus cyclophosphamide and TBI as conditioning for allogeneic matched sibling bone marrow transplants for acute myeloblastic leukaemia in first remission.
    Helenglass G; Powles RL; McElwain TJ; Lakhani A; Milan S; Gore M; Nandi A; Zuiable A; Perren T; Forgeson G
    Bone Marrow Transplant; 1988 Jan; 3(1):21-9. PubMed ID: 3048467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacokinetic evaluation of fluconazole in healthy volunteers].
    Shiba K; Saito A; Miyahara T
    Jpn J Antibiot; 1989 Jan; 42(1):17-30. PubMed ID: 2540363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Itraconazole can increase systemic exposure to busulfan in patients given bone marrow transplantation. GITMO (Gruppo Italiano Trapianto di Midollo Osseo).
    Buggia I; Zecca M; Alessandrino EP; Locatelli F; Rosti G; Bosi A; Pession A; Rotoli B; Majolino I; Dallorso A; Regazzi MB
    Anticancer Res; 1996; 16(4A):2083-8. PubMed ID: 8712747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Teniposide, doxorubicin, melphalan, cisplatin, and total body irradiation with autologous bone marrow transplantation for advanced neuroblastoma.
    Lam-Po-Tang PR; McCowage GB; Vowels MR
    Transplant Proc; 1993 Oct; 25(5):2881-2. PubMed ID: 8212272
    [No Abstract]   [Full Text] [Related]  

  • 18. Growth in children with poor-risk neuroblastoma after regimens with or without total body irradiation in preparation for autologous bone marrow transplantation.
    Hovi L; Saarinen-Pihkala UM; Vettenranta K; Lipsanen M; Tapanainen P
    Bone Marrow Transplant; 1999 Nov; 24(10):1131-6. PubMed ID: 10578163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is veno-occlusive disease incidence influenced by the total-body irradiation technique?
    Belkacémi Y; Ozsahin M; Rio B; Laporte JP; Leblond V; Pène F; Laugier A
    Strahlenther Onkol; 1995 Dec; 171(12):694-7. PubMed ID: 8545791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose therapy and autologous bone marrow transplantation for intermediate and high grade non-Hodgkin's lymphoma in patients aged 55 years and over: results from the European Group for Bone Marrow Transplantation. The EBMT Lymphoma Working Party.
    Sweetenham JW; Pearce R; Philip T; Proctor SJ; Mandelli F; Colombat P; Goldstone AH
    Bone Marrow Transplant; 1994 Dec; 14(6):981-7. PubMed ID: 7711677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.